A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT01242228

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01242228
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01242228. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10-21 (actual); primary completion 2012-06-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ipragliflozin
Intervention (Drug)
DPP-4 inhibitor
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01242228
Content hash
2885dc7aa3d302cb58015982c6ff0b0cdb3ed75005a2d44e25f9da6a4d5658f5